|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||33.69 - 34.04|
|52-week range||25.55 - 35.60|
|PE ratio (TTM)||22.19|
|Forward dividend & yield||0.90 (2.69%)|
|1y target est||38.00|
Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.
The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca
Roche shares were lifted on Monday by two trial wins for its new cancer and haemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines. Along with Roche's multiple sclerosis medicine Ocrevus, the drugs are pillars of Chief Executive Severin Schwan's plan to offset the patent expiry of top-sellers Rituxan, Avastin and Herceptin which account for $20 billion in annual sales. Roche said Tecentriq had cut the risk of lung cancer worsening when mixed with other treatments, while haemophilia agent Hemlibra had reduced bleeds in a new group of patients.
US civil rights activist Jesse Jackson disclosed that he has been diagnosed with Parkinson’s disease. Unfortunately for Jackson, and more than 10 million worldwide living with Parkinson's, there's no cure. However, a new partnership between AstraZeneca and Berg believes AI will be able to prevent it
Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial. It is a significant milestone for physicians, patients and investors, who are trying to assess the competitive landscape as drugmakers race to develop better ways to fight tumours in previously untreated lung cancer.
Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.
AstraZeneca’s (AZN) Oncology segment reported revenues of ~$1 billion during 3Q17, a 19% growth at constant exchange rates.
AstraZeneca’s (AZN) Respiratory segment is one of its key growth platforms. For 3Q17, the segment's revenues fell 2% at constant exchange rates to ~$1.1 billion.
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.
Brilinta reported 36% growth in revenues at constant exchange rates to $284 million, while foreign exchange impacted its revenues positively by 1% during 3Q17.
AstraZeneca Plc is in talks to settle a Texas lawsuit claiming that the company fleeced the state’s Medicaid program by fraudulently marketing one of its top drugs, according to court filings.
AstraZeneca's (AZN) overall revenue growth was 9%, driven by a substantial growth in externalization revenues to $1.~4 billion, partially offset by a 2% fall in product sales.
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.
AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's (FDA) decision to endorse benralizumab, which will be marketed under the name Fasenra, follows a positive recommendation for the product in Europe on Friday. Shares (Berlin: DI6.BE - news) in AstraZeneca were 1 percent higher on Wednesday following the overnight news.
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.
** AstraZeneca's immunotherapy drug Imfinzi enjoys enthusiastic editorial review in influential New England Journal of Medicine, following positive data reported in September from the Pacific stage III ...
Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. ...
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication for FASLODEX® , expanding the indication to include use with a